Sight Sciences Revenue and Competitors

Location

$108.7M

Total Funding

Estimated Revenue & Valuation

  • Sight Sciences's estimated annual revenue is currently $43.3M per year.(i)
  • Sight Sciences received $10.0M in venture funding in October 2017.
  • Sight Sciences's estimated revenue per employee is $166,385
  • Sight Sciences's total funding is $108.7M.
  • Sight Sciences's current valuation is $751.2M. (January 2022)

Employee Data

  • Sight Sciences has 260 Employees.(i)
  • Sight Sciences grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$19.1M76-3%N/AN/A
#2
$8M32-6%N/AN/A
#3
$5M20-9%N/AN/A
#4
$8.5M346%N/AN/A
#5
$5.3M21-9%N/AN/A
#6
$49.7M1980%N/AN/A
#7
$12M48N/AN/AN/A
#8
$8.5M3421%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$56.8M181-1%$199.1MN/A
Add Company

Sight Sciences, Inc. is a medical devices company based out of Menlo Park, California, United States.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$108.7M

Total Funding

260

Number of Employees

$43.3M

Revenue (est)

0%

Employee Growth %

$751.2M

Valuation

N/A

Accelerator

Sight Sciences News

2022-04-17 - Sight Sciences Announces Multiple Presentations and Event ...

Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and...

2022-04-06 - Sight Sciences - Opening My Eyes

Sight Sciences aims to transform ophthalmology and optometry through its proprietary devices which targets the underlying cause of prevalent eye...

2022-03-22 - Sight Sciences plots move into drug-device combos after ...

Buoyed by tens of millions in new revenue and a successful IPO that brought in proceeds of more than a quarter-billion dollars, Sight Sciences is scoping...

2021-03-04 - Sight Sciences Receives FDA Clearance for Expanded Indication for OMNI Surgical System

MENLO PARK, Calif., March 4, 2021 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company focused on addressing the underlying causes of the world's most prevalent eye conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the OMNI® Surgical ...

2020-12-01 - Sight Sciences Announces Substantial Crossover Raise

MENLO PARK, Calif., Dec. 1, 2020 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of its Series F Preferred Stock financing led by ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$750M2745%N/A
#2
$75M2747%N/A
#3
$0.4M27510%$236.7M
#4
$15M28021%N/A
#5
$76.7M28722%N/A

Sight Sciences Funding

DateAmountRoundLead InvestorsReference
2016-03-16$7.0MBHicks Equity PartnersArticle
2017-10-10$10.0MCAllegro Investment FundArticle